Emeset (Generic Ondansetron Hydrochloride Tablets)

Emeset (Generic Ondansetron HCl Tablets)
© The Swiss Pharmacy

Emeset (Generic Ondansetron Hydrochloride
Tablets) is indicated for the management of
nausea and vomiting induced by cytotoxic
chemotherapy and radiotherapy, and for the
prevention and treatment of post-operative
nausea and vomiting (PONV).

Emeset Tablets are
manufactured by Cipla
Limited, India in the strengths
of 4 mg and 8 mg.

Chemical Structure

The active ingredient contained in
Emeset tablets is Ondansetron
Hydrochloride.
Each Emeset tablet contains
Ondansetron Hydrochloride equivalent to
4 mg or 8 mg of Ondansetron.

Uses of Emeset 4 mg and 8 mg tablets:
Emeset (Generic Ondansetron Hydrochloride Tablets) is used to
treat the following indications:
Prevention of nausea and vomiting associated with highly
emetogenic cancer chemotherapy, including Cisplatin 50 mg/m2
or more.
Prevention of nausea and vomiting associated with initial and
repeat courses of moderately emetogenic cancer chemotherapy.
Prevention of nausea and vomiting associated with radiotherapy in
patients receiving total body irradiation, single high-dose fraction
to the abdomen, or daily fractions to the abdomen.

Uses of Emeset 4 mg and 8 mg tablets:
Emeset (Generic Ondansetron Hydrochloride Tablets) is used to
treat the following indications:
Prevention of postoperative nausea and/or vomiting. As with other
antiemetics, routine prophylaxis is not recommended for patients
in whom there is little expectation that nausea and/or vomiting will
occur postoperatively.
In patients where nausea and/or vomiting must be avoided
postoperatively, Ondansetron tablets, and syrup are
recommended even where the incidence of postoperative nausea
and/or vomiting is low.

Recommended Adult Dosage
The dose of Emeset (Generic Ondansetron Hydrochloride Tablets) for various
indications is given below:
Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer
Chemotherapy: The recommended adult oral dosage of Ondansetron is 24 mg given as
three 8-mg tablets administered 30 minutes before the start of single-day highly
emetogenic chemotherapy, including Cisplatin 50 mg/m2 or more.
Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer
Chemotherapy: The recommended adult oral dosage is one 8-mg ondansetron tablet
given twice a day. The first dose should be administered 30 minutes before the start of
emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-
mg Ondansetron tablet should be administered twice a day (every 12 hours) for 1 to 2
days after completion of chemotherapy.

Prevention of Nausea and Vomiting Associated With Radiotherapy, Either Total Body
Irradiation, or Single High-Dose Fraction or Daily Fractions to the Abdomen:
The recommended oral dosage is one 8-mg Ondansetron tablet given 3 times a day.
For total body irradiation, one 8-mg Ondansetron tablet should be administered 1 to 2
hours before each fraction of radiotherapy administered each day.
For single high-dose fraction radiotherapy to the abdomen, one 8-mg Ondansetron
tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses
every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
For daily fractionated radiotherapy to the abdomen, one 8-mg ondansetron tablet
should be administered 1 to 2 hours before radiotherapy, with subsequent doses every
8 hours after the first dose for each day radiotherapy is given.

Postoperative Nausea and Vomiting: The recommended dosage is 16 mg given
as two 8-mg Ondansetron tablets 1 hour before induction of anesthesia.
Impaired Renal Function: The dosage recommendation is the same as for the
general population. There is no experience beyond first-day administration of
Ondansetron.
Impaired Hepatic Function: In patients with severe hepatic impairment (Child-
Pugh2 score of 10 or greater), clearance is reduced and apparent volume of
distribution is increased with a resultant increase in plasma half-life. In such
patients, a total daily dose of 8 mg should not be exceeded.

Contraindications
➔Emeset is contraindicated in patients with a known
hypersensitivity to Ondansetron Hydrochloride or any
component of the tablet.
➔The concomitant administration of Apomorphine with
Ondansetron is contraindicated based on reports of
profound hypotension and loss of consciousness when
Apomorphine was administered with Ondansetron.

Storage Instructions
Emeset (Generic Ondansetron Hydrochloride
Tablets) have to be stored at controlled room
temperature i.e. from 20°C to 25°C (68°F to
77°F) with excursions permitted between 15° to
30°C (59° to 86°F).
Keep this as well as all other medicines away
from children and pets.

Warnings
Hypersensitivity reactions have been reported in patients who have
exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.
ECG changes including QT interval prolongation has been seen in
patients receiving Ondansetron. In addition, post-marketing cases of
torsade de pointes have been reported in patients using Ondansetron
Hydrochloride (Emeset tablets). Avoid ondansetron in patients with
congenital long QT syndrome. ECG monitoring is recommended in
patients with electrolyte abnormalities (e.g., hypokalemia or
hypomagnesemia), congestive heart failure, bradyarrhythmias or
patients taking other medicinal products that lead to QT prolongation.

Warnings
Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It
should not be used instead of nasogastric suction. The use of Ondansetron in
patients following abdominal surgery or in patients with chemotherapy-induced
nausea and vomiting may mask a progressive ileus and/or gastric distension.
Ondansetron does not itself appear to induce or inhibit the cytochrome P-450
drug-metabolizing enzyme system of the liver.
Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-
metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these
enzymes may change the clearance and, hence, the half-life of Ondansetron. On
the basis of available data, no dosage adjustment is recommended for patients
on these drugs.

Warnings
Based on reports of profound hypotension and loss of consciousness
when Apomorphine was administered with Ondansetron, concomitant
use of Apomorphine with ondansetron is contraindicated.
In patients treated with potent inducers of CYP3A4 (i.e., Phenytoin,
Carbamazepine, and Rifampicin), the clearance of Ondansetron was
significantly increased and Ondansetron blood concentrations were
decreased. However, on the basis of available data, no dosage
adjustment for Ondansetron is recommended for patients on these
medicines.

Warnings
Although no pharmacokinetic drug interaction between Ondansetron and
tramadol has been observed, data from 2 small studies indicate that
ondansetron may be associated with an increase in patient controlled
administration of Tramadol.
Tumor response to chemotherapy in the P-388 mouse leukemia model is not
affected by Ondansetron. In humans, carmustine, etoposide, and cisplatin do not
affect the pharmacokinetics of Ondansetron.
The coadministration of Ondansetron had no effect on the pharmacokinetics
and pharmacodynamics of Temazepam.

Warnings
Renal impairment: The dosage recommendation is the same as for the
general population. There is no experience beyond first-day
administration of Ondansetron (Emeset tablets) .
Hepatic impairment: In patients with severe hepatic impairment (Child-
Pugh2 score of 10 or greater), clearance is reduced and apparent volume
of distribution is increased with a resultant increase in plasma half-life. In
such patients, a total daily dose of 8 mg of Emeset tablets should not be
exceeded.

Possible Side Effects
The most common side effects reported in greater than or equal to 4% of 300
adults receiving a single 24 mg dose of Ondansetron Hydrochloride (Emeset
tablets) orally in 2 trials for the prevention of nausea and vomiting associated
with highly emetogenic chemotherapy (Cisplatin greater than or equal to 50
mg/m2) were: headache (11%) and diarrhea (4%).
The most common Ondansetron Hydrochloride (Emeset tablets) side effects
reported in 4 trials in adults for the prevention of nausea and vomiting
associated with moderately emetogenic chemotherapy (primarily
cyclophosphamide-based regimens) reported in greater than or equal to 5% of
patients treated with ondansetron and at a rate that exceeded placebo include
Headache, Malaise/fatigue, Constipation and Diarrhea.

Possible Side Effects
The other less common Ondansetron Hydrochloride (Emeset tablets) side effects include:
Central Nervous System: Extrapyramidal reactions (less than 1% of patients).
Hepatic: Aspartate transaminase (AST) and/or alanine transaminase (ALT) values exceeded
twice the upper limit of normal in approximately 1% to 2% of 723 patients receiving
Ondansetron and cyclophosphamide-based chemotherapy in U.S. clinical trials.
Liver failure and death has been reported in cancer patients receiving concurrent medications,
including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the
liver failure is unclear.
Integumentary: Rash (approximately 1% of patients).
Other (less than 2%): Anaphylaxis, bronchospasm, tachycardia, angina, hypokalemia,
electrocardiographic alterations, vascular occlusive events, and grand mal seizures. Except for
bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear.

Ondansetron (Emeset tablets) Overdosage
There is no specific antidote for Ondansetron Hydrochloride
(Emeset tablets) overdose. Patients should be managed with
appropriate supportive therapy.
Individual intravenous doses as large as 150 mg and total
daily intravenous doses as large as 252 mg have been
inadvertently administered without significant adverse
events. These doses are more than 10 times the
recommended daily dose.

Ondansetron (Emeset tablets) Overdosage
In addition to the adverse events listed above, the following events
have been described in the setting of Ondansetron (Emeset tablets)
overdose: “Sudden blindness” (amaurosis) of 2 to 3 minutes' duration
plus severe constipation occurred in 1 patient that was administered
72 mg of ondansetron intravenously as a single dose.
Hypotension (and faintness) occurred in a patient that took 48 mg of
ondansetron tablets. Following infusion of 32 mg over only a 4-minute
period, a vasovagal episode with transient second-degree heart block
was observed. In all instances, the events resolved completely.

Emeset Tablets During Pregnancy
Ondansetron Hydrochloride (Emeset tablets) has been classified by
the US FDA as Pregnancy Category B.
Reproduction studies have been performed in pregnant rats and
rabbits at daily oral doses up to 15 and 30 mg/kg/day, respectively,
and have revealed no evidence of impaired fertility or harm to the
fetus due to Ondansetron.
There are, however, no adequate and well-controlled studies in
pregnant women. Because animal reproduction studies are not
always predictive of human response, Emeset tablets should be used
during pregnancy only if clearly needed.

Emeset Tablets are manufactured by Cipla
Limited, India.
For More details Click Here

Emeset (Generic Ondansetron Hydrochloride Tablets)

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Emeset (Generic Ondansetron Hydrochloride Tablets)

Similar to Emeset (Generic Ondansetron Hydrochloride Tablets) (20)

More from The Swiss Pharmacy

More from The Swiss Pharmacy (20)

Recently uploaded

Recently uploaded (20)

Emeset (Generic Ondansetron Hydrochloride Tablets)